They demonstrated that anti-CTLA-4 monoclonal antibody IPI combined with radiotherapy made the tumor substantially subsided in both clinical trials and mouse models of metastatic melanoma, although drug resistance can be a potential concern. The gene discussed is CTLA4; the disease is neoplasm.